-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports from Yimaike ★Nanjing in May · Big coffee gathered2021 nucleic acid drug development forum announced schedule ★ May Nanjing2021 nucleic acid drug development forum is about to open April 27, 2021 / Yimaike news eMedClub News/--Recently, clinical Phase 1 biotechnology company Istari Oncology announced the Phase 1 clinical data of its oncolytic virus therapy PVSRIPO for patients with unresectable and refractory melanoma.
The data shows that PVSRIPO is effective for PD-1 and BRAF targeted therapy in patients with refractory advanced melanoma.
hope.
PVSRIPO is a viral immunotherapy, derived from Sabin 1 polio vaccine, which has been engineered to improve safety and immunogenicity.
The therapy can activate the patient's innate and adaptive immune system, thereby promoting anti-tumor immune response, establishing long-term immune memory, and preventing cancer recurrence.
Unlike most viral immunotherapies, PVSRIPO has a well-characterized target, targeting the poliovirus receptor CD155, which is expressed in most solid tumors and antigen-presenting cells.
PVSRIPO has been granted breakthrough therapy designation and orphan drug designation for the treatment of recurrent glioblastoma by the FDA; and orphan drug designation for the treatment of advanced melanoma.
▲PVSRIPO mechanism of action (picture source: istarioncology.
com) In the latest published data, a total of 12 patients received intratumoral injection of PVSRIPO, and patients received 1/2/3 PVSRIPO every 21 days.
In the cohort that received 3 injections (n=6), 60% (4/6) of the patients achieved considerable remission, of which 3 received PD-1 treatment 30 days ago, which means that PVSRIPO can be restarted/activated Immune response of PD-1 refractory patients.
At the same time, PVSRIPO produces a functional anti-tumor CD8 + T cell response, which can mediate effective systemic anti-tumor immunity.
After the study, 11 patients (n=12) were re-treated with immune checkpoint inhibitors, and 50% (6/12) of the patients were followed up for a median of 18 months and the disease did not progress.
According to the observed anti-tumor The response indicates that VSRIPO alone or in combination with anti-PD-1 may be an effective treatment for anti-PD-1 refractory melanoma.
The 2021 nucleic acid drug development forum will kick off in Nanjing from May 7th to 8th, 2021, to welcome the "new era of super drugs".
The data shows that PVSRIPO is effective for PD-1 and BRAF targeted therapy in patients with refractory advanced melanoma.
hope.
PVSRIPO is a viral immunotherapy, derived from Sabin 1 polio vaccine, which has been engineered to improve safety and immunogenicity.
The therapy can activate the patient's innate and adaptive immune system, thereby promoting anti-tumor immune response, establishing long-term immune memory, and preventing cancer recurrence.
Unlike most viral immunotherapies, PVSRIPO has a well-characterized target, targeting the poliovirus receptor CD155, which is expressed in most solid tumors and antigen-presenting cells.
PVSRIPO has been granted breakthrough therapy designation and orphan drug designation for the treatment of recurrent glioblastoma by the FDA; and orphan drug designation for the treatment of advanced melanoma.
▲PVSRIPO mechanism of action (picture source: istarioncology.
com) In the latest published data, a total of 12 patients received intratumoral injection of PVSRIPO, and patients received 1/2/3 PVSRIPO every 21 days.
In the cohort that received 3 injections (n=6), 60% (4/6) of the patients achieved considerable remission, of which 3 received PD-1 treatment 30 days ago, which means that PVSRIPO can be restarted/activated Immune response of PD-1 refractory patients.
At the same time, PVSRIPO produces a functional anti-tumor CD8 + T cell response, which can mediate effective systemic anti-tumor immunity.
After the study, 11 patients (n=12) were re-treated with immune checkpoint inhibitors, and 50% (6/12) of the patients were followed up for a median of 18 months and the disease did not progress.
According to the observed anti-tumor The response indicates that VSRIPO alone or in combination with anti-PD-1 may be an effective treatment for anti-PD-1 refractory melanoma.
The 2021 nucleic acid drug development forum will kick off in Nanjing from May 7th to 8th, 2021, to welcome the "new era of super drugs".
